Quizartinib is a tyrosine kinase inhibitor (TKI) indicated for newly diagnosed adult patients with FLT3-ITD mutation-positive acute myeloid leukemia (AML) in combination with standard cytarabine and anthracyclines for induction chemotherapy, followed by cytarabine consolidation chemotherapy, and then as maintenance monotherapy after consolidation chemotherapy.
Restrictions: Quizartinib is not indicated for maintenance monotherapy after hematopoietic stem cell transplantation (HSCT) because it has not been proven to improve overall survival (OS) in this case.
